Miransertib hydrochlorideCAS号1313883-00-9
Miransertib hydrochlorideCAS号1313883-00-9

Miransertib hydrochloride

¥608.90 ~¥10,299.90
100mg / 10mg / 250mg / 25mg / 50mg / 5mg
100mg
上海
阿拉丁
2025-04-25
我要询单 立即交流 查看联系方式
上海阿拉丁生化科技股份有限公司
手机号: 13167063860
电话: 13167063860
联系人: 阿拉丁
联系QQ: 3004013043
邮箱: anhua.mao@aladdin-e.com
企业微信 企业微信
个人微信 个人微信
电话邮箱等咨询请告知是在960化工网上看到的,谢谢!
产品详情
中文名称:Miransertib hydrochloride中文别名:Miransertib hydrochloride
英文名称:Miransertib hydrochlorideCAS:1313883-00-9
产品分类:纯度:≥99%
产品编号品牌纯度规格库存价格
M413976阿拉丁≥99%100mg现货5,149.90 元
M413976阿拉丁≥99%10mg现货1,174.90 元
M413976阿拉丁≥99%250mg现货10,299.90 元
M413976阿拉丁≥99%25mg现货1,752.90 元
M413976阿拉丁≥99%50mg现货3,295.90 元
M413976阿拉丁≥99%5mg现货608.90 元
标准名称:Miransertib (ARQ 092) HCl英文名称:Miransertib HCl
CAS:1313883-00-9分子式:C27H25ClN6
分子量:468.980603933334颜色与性状:
密度:沸点:
熔点:水溶性:

中文名:Miransertib hydrochloride

英文名:Miransertib hydrochloride

纯度:≥99%

货号:M413976

Cas号:1313883-00-9

存储温度:-20°C储存

运输条件:超低温冰袋运输

产品介绍:

Information

Miransertib (ARQ 092) HCl is a novel, orally bioavailable and selectiveAKT pathwayinhibitor exhibiting a manageable safety profile among patients with advanced solid tumors.


Targets

Akt2 (Cell-free assay); Akt1 (Cell-free assay); Akt3 (Cell-free assay) 4.5 nM; 5 nM; 16 nM


In vitro

ARQ 092 blocks membrane translocation of inactive AKT and even dephosphorylates the membrane-associated active form, thereby perturbing AKT activity. Treatment with 50-500 nM ARQ 092 significantly blocks αMβ2 integrin function in neutrophils and reduces P-selectin exposure and glycoprotein Ib/IX/V-mediated agglutination in platelets. In a large panel of diverse cancer cell lines, ARQ 092 inhibits proliferation across multiple tumor types but are most potent in leukemia, breast, endometrial, and colorectal cancer cell lines. Moreover, inhibition by ARQ 092 is more prevalent in cancer cell lines containing PIK3CA/PIK3R1 mutations compared to those with wt-PIK3CA/PIK3R1 or PTEN mutations. ARQ 092 targets the PI3K/AKT pathway and AKT specifically and reduces phosphorylation of GSK3α and GSK3β in mutation-positive cells.


In vivo

Short-term oral administration of ARQ 092 or hydroxyurea, a main therapy for sickle cell disease, diminishes heterotypic cell-cell interactions in venules of sickle cell disease mice challenged with TNF-α. ARQ 092 is well tolerated at a continuous daily dose of 60 mg or a dose of 600 mg when administered once a week, for several months. ARQ 092 is likely to inhibit the activity of all AKT isoforms in intravascular cells and thereby attenuates the process of thrombosis and inflammation in SCD patients. ARQ 092 is highly active in a subset of endometrial tumors that harbor PI3K pathway gene mutations.


Cell Research(from reference)

Cell lines:MDA-MB-453 cells; NCI-H1650 cells; KU-19-19 cells

Concentrations:0, 0.012, 0.037, 0.11, 0.33, and 1 μM

Incubation Time:2 h


查看阿拉丁官网此产品相关对应页面:http://www.aladdin-e.com/zh_cn/M413976.html


公司简介
阿拉丁是A股科创板上市企业(股票代码:688179),同时也是科学服务领域集研发、生产和制造一体的高科技企业。公司业务涵盖高端化学、生命科学、分析色谱及材料科学四大领域的试剂和研发材料。公司自主打造“阿拉丁”品牌科研试剂和“芯硅谷”品牌实验耗材,主要依托自身电子商务平台www.aladdin-e.com)实现线上销售。公司在上海建有64000平方米的研发和生产基地。同时在华东、华北、华南和西南拥有现代化物流仓库,另外华中仓正在建设中,预计2022年上半年将投入使用,这将优化客户体验,缩短客户的交货时间。



公司科研试剂产品广泛应用于高等院校、科研院所以及生物医药、新材料、新能源、节能环保、航空航天等高新技术产业和战略性新兴产业相关企业的研发机构。截至2021年底,公司科研试剂常备库存产品超过7.5万种,是国内品种最齐全的试剂供应商之一;拥有注册用户超过14.5万名,直接客户有科研院所、高等院校(覆盖全部985工程大学、90%以上211工程大学)以及各战略新兴行业内创新型企业群体(覆盖220余家A股上市公司)。